BiotechTube

Niaspan

Pre-clinicalUNKNOWN
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis

Trial Timeline

Sep 1, 2004 โ†’ Feb 1, 2009

NCT ID
NCT00232531

About Niaspan

Niaspan is a pre-clinical stage product being developed by Merck for Atherosclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00232531. Target conditions include Atherosclerosis.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00232531Pre-clinicalUNKNOWN

Competing Products

20 competing products in Atherosclerosis

See all competitors
ProductCompanyStageHype Score
Orforglipron + PlaceboEli LillyPhase 3
77
Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3
77
Pactimibe sulfateDaiichi SankyoPhase 2/3
65
PactimibeDaiichi SankyoPhase 2
52
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3
77
Micronized 17B-estradiolJohnson & JohnsonPhase 2/3
65
Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
85
Rosuvastatin + PlaceboAstraZenecaApproved
85
rosuvastatin + placeboAstraZenecaPhase 1
33
Rosuvastatin + PlaceboAstraZenecaPhase 1
33
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
Rosuvastatin + PlaceboAstraZenecaPhase 3
77
Rosuvastatin (5mg๏ผŒ10mg๏ผŒ20mg) + Rosuvastatin 5mgAstraZenecaApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
Vorapaxar + Placebo + Aspirin + ClopidogrelMerckPhase 2
52
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
85
lovastatinMerckPhase 2/3
65
Ezetimibe + PlaceboMerckApproved
85
Vorapaxar + PlaceboMerckPhase 3
77
MK0633MerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
MavencladยฎApproved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85